The American Recovery and Reinvestment Act (ARRA) Signature Project Program provides research support for a limited time (up to 24 months) to enable eligible investigators to develop novel human islet cell replacement therapies for diabetes. While insulin replacement therapy has transformed type 1 diabetes (T1D) from a fatal disease to a chronic one, it is still associated with significant morbidity. Complications of diabetes lead to kidney failure, blindness, amputations, and urologic complications, while diabetes increases the risk of macrovascular disease by 2-4 fold. Intensive therapy is associated with significant adverse events related to hypoglycemia. Thus, a restoration of pancreatic function through transplantation or regeneration would be a vast improvement over current practice.
2009-2010 ARRA Collaboration Network
Project team leaders are flagged with a yellow star, .
Generation and Differentiation of PSiPSIIC (Patient-Specific iPS cells to Insulin-secreting Islet-like Clusters)
Differentiation of iPS cells from type 1 diabetics into hematopoietic stem cells
Diabetic Stem Cell Modeling of Human Disease